• Sionna Therapeutics director Peter A. Thompson reported sales of 292,952 common shares on May 7-11.
• Shares were sold at prices ranging from $44.58 to $46.22.
• Beneficial ownership following transactions totaled 2,671,822 shares, held indirectly.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sionna Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000947871-26-000518), on May 11, 2026, and is solely responsible for the information contained therein.